OBJECTIVE: This study was intended to determine the incidence rate of warfarin-related adverse events (e.g., bleeding) in Puerto Ricans and whether a genetic association between warfarin pharmacogenes and any of these adverse events was observed over the initiation period (i.e., the first 90 days of therapy). METHODS: We conducted an observational, retrospective cohort study of pharmacogenetic association in 122 warfarin-treated, male, Puerto Rican patients (69.9 +/- 9.6 years) from the Veterans Affair Caribbean Healthcare System (VACHS) who consented to participate. Genotyping was performed using the CYP2C9 and VKORC1 assays by Luminex. Event-free survival curves were estimated using the Kaplan-Meier method and analyzed by log-rank test. Cox regression models were constructed and hazard ratios (HR) calculated. RESULTS: Carriers of functional CYP2C9 and VKORC1 polymorphisms demonstrated a higher incidence rate of multiple adverse events (i.e., 5.2 vs. 1.0 cases per 100 patient-months; RR = 4.8, p = 0.12) than did wild types. A significant association was observed between multiple adverse events and carrier status (HR = 2.5; 95% CI: 1.0-6.3, p = 0.04). However, no significant associations between genotypes and individual outcomes over the first 90 days of therapy were found. CONCLUSION: The association of CYP2C9 and VKORC1 genotypes and risks for adverse events due to exposure to warfarin was examined for the first time in Puerto Ricans. Despite a lack of association with individual events in this study population, our findings revealed a potential utility of genotyping for the prevention of multiple adverse events during warfarin therapy.
OBJECTIVE: This study was intended to determine the incidence rate of warfarin-related adverse events (e.g., bleeding) in Puerto Ricans and whether a genetic association between warfarin pharmacogenes and any of these adverse events was observed over the initiation period (i.e., the first 90 days of therapy). METHODS: We conducted an observational, retrospective cohort study of pharmacogenetic association in 122 warfarin-treated, male, Puerto Rican patients (69.9 +/- 9.6 years) from the Veterans Affair Caribbean Healthcare System (VACHS) who consented to participate. Genotyping was performed using the CYP2C9 and VKORC1 assays by Luminex. Event-free survival curves were estimated using the Kaplan-Meier method and analyzed by log-rank test. Cox regression models were constructed and hazard ratios (HR) calculated. RESULTS: Carriers of functional CYP2C9 and VKORC1 polymorphisms demonstrated a higher incidence rate of multiple adverse events (i.e., 5.2 vs. 1.0 cases per 100 patient-months; RR = 4.8, p = 0.12) than did wild types. A significant association was observed between multiple adverse events and carrier status (HR = 2.5; 95% CI: 1.0-6.3, p = 0.04). However, no significant associations between genotypes and individual outcomes over the first 90 days of therapy were found. CONCLUSION: The association of CYP2C9 and VKORC1 genotypes and risks for adverse events due to exposure to warfarin was examined for the first time in Puerto Ricans. Despite a lack of association with individual events in this study population, our findings revealed a potential utility of genotyping for the prevention of multiple adverse events during warfarin therapy.
Authors: Mitchell K Higashi; David L Veenstra; L Midori Kondo; Ann K Wittkowsky; Sengkeo L Srinouanprachanh; Fred M Farin; Allan E Rettie Journal: JAMA Date: 2002-04-03 Impact factor: 56.272
Authors: Elizabeth A Sconce; Tayyaba I Khan; Hilary A Wynne; Peter Avery; Louise Monkhouse; Barry P King; Peter Wood; Patrick Kesteven; Ann K Daly; Farhad Kamali Journal: Blood Date: 2005-06-09 Impact factor: 22.113
Authors: Vincent J Willey; Michael F Bullano; Ole Hauch; Matthew Reynolds; Gail Wygant; Lauren Hoffman; George Mayzell; Alex C Spyropoulos Journal: Clin Ther Date: 2004-07 Impact factor: 3.393
Authors: Margaret C Fang; Yuchiao Chang; Elaine M Hylek; Jonathan Rosand; Steven M Greenberg; Alan S Go; Daniel E Singer Journal: Ann Intern Med Date: 2004-11-16 Impact factor: 25.391
Authors: Carolina Céspedes-Garro; María-Eugenia G Naranjo; Fernanda Rodrigues-Soares; Adrián LLerena; Jorge Duconge; Lazara K Montané-Jaime; Hilda Roblejo; Humberto Fariñas; María de Los A Campos; Ronald Ramírez; Víctor Serrano; Carmen I Villagrán; Eva M Peñas-LLedó Journal: Pharmacogenomics Date: 2016-09-16 Impact factor: 2.533
Authors: Carlos Martes-Martinez; Cristian Méndez-Sepúlveda; Joel Millán-Molina; Matthew French-Kim; Heriberto Marín-Centeno; Giselle C Rivera-Miranda; José J Hernández-Muñoz; Jorge Duconge-Soler Journal: P R Health Sci J Date: 2017-09 Impact factor: 0.705
Authors: J S Floyd; C M Sitlani; C L Avery; R Noordam; X Li; A V Smith; S M Gogarten; J Li; L Broer; D S Evans; S Trompet; J A Brody; J D Stewart; J D Eicher; A A Seyerle; J Roach; L A Lange; H J Lin; J A Kors; T B Harris; R Li-Gao; N Sattar; S R Cummings; K L Wiggins; M D Napier; T Stürmer; J C Bis; K F Kerr; A G Uitterlinden; K D Taylor; D J Stott; R de Mutsert; L J Launer; E L Busch; R Méndez-Giráldez; N Sotoodehnia; E Z Soliman; Y Li; Q Duan; F R Rosendaal; P E Slagboom; K C Wilhelmsen; A P Reiner; Y-Di Chen; S R Heckbert; R C Kaplan; K M Rice; J W Jukema; A D Johnson; Y Liu; D O Mook-Kanamori; V Gudnason; J G Wilson; J I Rotter; C C Laurie; B M Psaty; E A Whitsel; L A Cupples; B H Stricker Journal: Pharmacogenomics J Date: 2016-12-13 Impact factor: 3.550